Johnson & Johnson has launched Generation Fine, a global initiative designed to challenge the quiet acceptance of “good enough” in depression care and encourage patients to expect more from their treatment. The effort comes on the heels of a global survey finding that nearly 4 in 5 people living with major depressive disorder don’t believe antidepressants will address all of their symptoms or help them reach remission — a sobering reminder of how low the bar has been set in the minds of many patients.

Built alongside mental health advocates and grounded in lived experience, Generation Fine offers resources, patient stories, and conversation tools that clinical teams can point patients to when discussing treatment goals. For sites working with MDD populations, this kind of patient-facing material can open doors to deeper conversations about symptom burden, unmet needs, and what meaningful improvement actually looks like.

Visit Generation-Fine.com to explore the full suite of resources.